SI
VRTX icon

Sava Infond’s Vertex Pharmaceuticals VRTX Stock Holding History

Sava Infond’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$671K Sell
1,350
-200
-13% -$88.6K 0.05% 128
2026
Q1 		$692K Sell
1,550
-20
-1% -$9.33K 0.1% 118
2025
Q4 		$712K Hold
1,570
– – 0.1% 119
2025
Q3 		$615K Hold
1,570
– – 0.09% 121
2025
Q2 		$699K Hold
1,570
– – 0.11% 112
2025
Q1 		$761K Sell
1,570
-60
-4% -$28K 0.15% 101
2024
Q4 		$656K Buy
+1,630
New +$756K 0.12% 104

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Sava Infond's VRTX Position: Q2 2026 in Review

Sava Infond reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, selling an estimated $88.6K and leaving 1,350 shares worth $671K. The position accounts for 0.05% of the portfolio, ranked #128.

Sava Infond first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $761K in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sava Infond held 1,350 shares of Vertex Pharmaceuticals worth $671K as of Q2 2026.
  • Sava Infond sold 200 Vertex Pharmaceuticals shares in Q2 2026, an estimated $88.6K.
  • Vertex Pharmaceuticals made up 0.05% of Sava Infond's portfolio in Q2 2026, its #128 holding.
  • Sava Infond first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Sava Infond's Vertex Pharmaceuticals position peaked at $761K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sava Infond's 13F filing for Q2 2026, filed 16 Jul 2026.